| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| huperzine A is a natural product and has been studied for its potential benefits in Alzheimer's disease (AD). -inhibits acetylcholinesterase(AChE), the enzyme that breaks down acetylcholine, a key neurotransmitter involved in memory and learning. Huperzine A / Huperzia serrata — Huperzine A (HupA) is a naturally occurring Lycopodium alkaloid isolated principally from Huperzia serrata (Chinese club moss) and related Huperziaceae species. It is a centrally active, reversible acetylcholinesterase inhibitor with good blood-brain-barrier penetration and additional preclinical neuroprotective actions. It is best classified as a plant-derived alkaloid / cholinesterase inhibitor rather than as an herbal extract: purified Huperzine A and whole-plant Huperzia serrata preparations should not be considered pharmacologically equivalent because plant extracts contain variable HupA concentrations and additional alkaloids. HupA has been investigated primarily for Alzheimer's disease and other cognitive disorders; clinical evidence is substantially stronger for purified HupA than for generic H. serrata supplements. Primary mechanisms (ranked):
Bioavailability / PK relevance: Huperzine A is orally active and reaches the central nervous system. Human pharmacokinetic studies indicate biphasic elimination with a terminal half-life of approximately 12 hours, supporting sustained cholinesterase inhibition after relatively small oral doses. Purified HupA has much more predictable pharmacokinetics than whole-herb H. serrata preparations, for which actual HupA exposure depends on extraction and standardization. In-vitro vs systemic exposure relevance: The direct AChE-inhibitory effect is pharmacologically relevant at clinically attainable exposure. Some broader neuroprotective experiments use micromolar HupA concentrations, including approximately 10 µM in neuronal cell models, which may exceed concentrations achieved after conventional oral dosing; these signaling, antioxidant and anti-apoptotic mechanisms therefore require greater caution when extrapolated to humans. Clinical evidence status: Human RCT evidence exists for Alzheimer's disease, but efficacy remains insufficiently established for routine Western medical use. A U.S. multicenter phase II trial found that 200 µg twice daily did not significantly improve the primary cognitive endpoint, while 400 µg twice daily produced a signal on some cognitive measures and was generally tolerated for 24 weeks. Several earlier Chinese trials and meta-analyses report cognitive benefit but have important methodological limitations. Huperzine A is not an FDA-approved Alzheimer's treatment; products marketed in the United States are generally dietary supplements rather than approved AD drugs. Clinical development remains active, including controlled-release HupA trials in dementia. Alzheimer's Disease Mechanisms
TSF: P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| Also known as CP32. Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death. As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression. Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy. Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent. On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer. Procaspase-3 is a apoptotic marker protein. Prognostic significance: • High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers. • Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers. |
| 4209- | Hup, | Huperzine A, reduces brain iron overload and alleviates cognitive deficit in mice exposed to chronic intermittent hypoxia |
| - | in-vivo, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:343 Target#:42 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid